Trial Profile
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Cemiplimab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWER-CSCC 1; R2810-ONC-1540
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 08 Mar 2024 This study has been Completed in Italy, According to European Clinical Trials Database record.
- 17 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results from group 6 (n=165, as of data cut off date of Oct 25 2021) assessing additional efficacy and safety presented at the 47th European Society for Medical Oncology Congress.